Hims Could See Near-Term Headwinds From Novo Partnership -- Market Talk
Dow Jones
Mar 09
0849 ET - Hims & Hers shares jumped on the news that Novo Nordisk will end its lawsuit against the company and Hims will offer Novo GLP-1s on its platform. That removes a significant legal overhang for Hims, but the partnership could be a near-term hit to its business, say Truist analysts. As part of the deal, Hims will no longer offer compounded GLP-1 drugs, which previously composed a large chunk of its revenue. Still the durability of revenue from branded GLP-1s is much higher, especially given the legal threats Hims' compounded drugs faced. That may make investors willing to assign a higher multiple to Hims, the analysts say. Hims shares climb 51% premarket. (nicholas.miller@wsj.com)
(END) Dow Jones Newswires
March 09, 2026 08:49 ET (12:49 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.